Soranife 200 Tablet contains Sorafenib 200mg, a targeted anticancer agent used in the management of advanced liver cancer (hepatocellular carcinoma), kidney cancer (renal cell carcinoma), and thyroid cancer. It helps in controlling cancer progression and improving treatment outcomes.
Sorafenib works by inhibiting multiple protein kinases involved in tumor cell growth and abnormal blood vessel formation. By blocking these pathways, it helps in slowing tumor proliferation and reducing cancer spread.
This medicine is commonly prescribed in advanced or metastatic cancer cases, where targeted therapy is required as part of long-term oncology treatment. Its oral dosage form supports convenient administration and better patient compliance.
For PCD pharma franchise partners, Soranife 200 Tablet is a high-value oncology product, available at best price for PCD pharma franchise. Its strong clinical demand, specialist prescription base, and consistent market requirement make it a strategic addition to any cancer care portfolio.
Common side effects may include fatigue, diarrhea, rash, hand-foot skin reaction, nausea, and hypertension. Rare but serious side effects include liver toxicity, severe bleeding, cardiac events, or severe allergic reactions. Patients should report any severe or persistent symptoms to their doctor immediately.
Soranife 200 Tablet is indicated for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and certain thyroid cancers, as prescribed by a healthcare professional.
Soranife 200 Tablet should be taken exactly as prescribed, usually on an empty stomach, and under strict medical supervision. Regular monitoring of liver function, blood pressure, and overall health is essential. Inform the doctor of any existing heart, liver, or kidney problems and all medications being taken to avoid interactions.
Store Soranife 200 Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and do not use beyond the expiry date printed on the packaging.